QT-prolongation in Psychiatric Hospitals
Overview
Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2015
Interventions
- Drug: drugs linked with QT-prolongation
- all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
Arms, Groups and Cohorts
- psychiatric patients treated with QT-prolonging drugs
Clinical Trial Outcome Measures
Primary Measures
- change in QTc-interval (corrected for heart rate)
- Time Frame: before and one week after the start of a QT-prolonging drug
Participating in This Clinical Trial
Inclusion Criteria
- inpatient in one of the 6 participating psychiatric hospitals – QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug Exclusion Criteria:
- age < 18 year
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- KU Leuven
- Collaborator
- Agentschap voor Innovatie door Wetenschap en Technologie
- Provider of Information About this Clinical Study
- Principal Investigator: Eline Vandael, PhD-student – KU Leuven
- Overall Official(s)
- Eline Vandael, PhD-student, Principal Investigator, KU Leuven
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.